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ABSTRACT
Objectives Healthcare expenditure per-capita in the USA 
is higher than in England. We hypothesised that clinical 
outcomes after cardiac revascularisation are better in 
the USA. We compared costs and outcomes of patients 
undergoing coronary artery bypass grafting (CABG) and 
percutaneous coronary intervention (PCI) in England and New 
York State (NYS).
Methods Costs and total mortality were assessed using the 
Hospital Episode Statistics for England and the Statewide 
Planning and Research Cooperative System for NYS. 
Outcomes after a first CABG or PCI were assessed in patients 
undergoing a first CABG (n=142 969) or PCI (n=431 416).
Results After CABG, crude total mortality in England was 
0.72% lower at 30 days and 3.68% lower at 1 year (both 
P<0.001). After PCI, crude total mortality was 0.35% lower 
at 30 days and 3.55% lower at 1 year (both P<0.001). No 
differences emerged in total mortality at 30 days after either 
CABG (England: HR 1.02,95% CI 0.94 to 1.10) or PCI (HR 
1.04, 95% CI 0.99 to 1.09) after covariate adjustment. At 
1 year, adjusted total mortality was lower in England after 
both CABG (HR 0.74, 95% CI 0.71 to 0.78) and PCI (HR 0.66, 
95% CI 0.65 to 0.68). After adjustment for cost-to-charge 
ratios and purchasing power parities, costs in NYS amounted 
to uplifts of 3.8-fold for CABG and 3.6-fold for PCI.
Conclusions Total mortality after CABG and PCI was 
similar at 30 days and lower in England at 1 year. Costs 
were approximately fourfold higher in NYS.
IntROduCtIOn
The USA spends more per capita on health-
care than any other developed nation. This 
high expenditure underlies the perception 
that the quality of healthcare in the USA is 
better than in a public health system. Despite 
the most expensive healthcare system, the USA 
ranks poorly in comparison to other industri-
alised countries on measures of health system 
performance, with respect to quality, efficiency, 
access to care and equity.1 
Amidst the current political imperative to 
reform healthcare in the USA, most Ameri-
cans consider that they receive the best quality 
of care2 and that a public healthcare system 
would undermine quality.3 4 On the other 
hand, the National Health Service (NHS) in 
England is popularly regarded as a compro-
mise between ‘best care’ and limited resources, 
in the context of its fundamental premise that 
healthcare will be provided to everyone ‘free at 
the point of delivery’.
Cardiovascular disease is a major contrib-
utor to total healthcare costs in the Western 
World. In the UK, direct annual costs amount 
to £17.4 billion, which is 18% of total UK 
healthcare costs.5 Including indirect costs, 
the total cost of heart disease amounts to 
£29.1 billion in the UK and $215.6 billion in 
the USA (2011).6 The cost of cardiovascular 
disease in the USA is projected to rise from 
$656 billion in 2015 to $1208 billion in 2030.6 
Such a high cost burden begs a comparison of 
costs and outcomes of cardiovascular proce-
dures in the USA and England. In this study, 
we explore the costs and long-term outcomes 
of coronary artery bypass grafting (CABG) and 
percutaneous coronary intervention (PCI). 
To this end, we have employed administrative 
databases, namely the Hospital Episode Statis-
tics (HES) and Office of National Statistics 
for England and the Statewide Planning and 
Research Cooperative System (SPARCS) for 
New York State (NYS).
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Key messages
What is already known about this subject?
 ► Healthcare expenditure per-capita in the USA is 
higher than in England.
What does this study add?
 ► Survival after coronary artery bypass grafting 
(CABG) and percutaneous coronary intervention 
(PCI) in England at 1 year is better than in New 
York State (NYS), at much lower costs, taking into 
account cost of living.
How might this impact on clinical practice?
 ► Survival after CABG and PCI in NYS may be 
achievable at the cost levels observed in England.
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MetHOds
data sources
In this non-randomised, retrospective study, clinical and 
outcome data were extracted from HES and SPARCS. 
These are data warehouses containing details of all 
admissions to all NHS hospitals in England and all NYS 
hospitals, including patient demographics, diagnoses 
and treatments and services. In both systems, no personal 
identification is disclosed, so as to protect patient confi-
dentiality. Data from HES are available to University 
Hospital Birmingham under a data sharing agreement 
for the purposes of service evaluation (section 251 of the 
NHS Act 2006). For SPARCS, an agreement has been 
drawn with NYS Department of Health to use anonymised 
data for comparisons of clinical outcomes between hospi-
tals and healthcare systems. The study conforms to the 
Declaration of Helsinki.
Our sample from both England and NYS includes unse-
lected patients undergoing a first CABG and PCI between 
1 April 2009 and 1 December 2013. Only data relating to 
the first procedure were used in analyses. In NYS, data 
were collected with reference to International Coding 
of Diseases Ninth Revision (ICD-9), whereas ICD-10 was 
used in the England dataset. Mapping of relevant codes 
between ICD-9 and ICD-10 is listed in the online supple-
mentary appendix.
Costs
The NHS in England is funded through national tariff, 
which is set for each year. It is calculated on ‘Payment by 
Results’, according to which payment is linked to activity 
and adjusted for case mix. In NYS, SPARCS provides indi-
vidualised, discharge level gross charges but not costs. 
We therefore converted the gross charges to average 
cost for each year by adjusting for Medicare hospital-spe-
cific cost-to-charge ratios (CCRs) from the relevant year 
using the Inpatient Prospective Payment System Impact 
File.7 8 Average CCRs of 0.43–0.45 were used for the 
period 2009–2013. Instead of applying nominal exchange 
rates for US dollars and pound sterling, we also adjusted 
for purchasing power parities (PPPs), which yield an esti-
mate of the exchange rate between two currencies would 
have to be in order for the exchange to be in line with 
the purchasing power of the two countries’ currencies. In 
effect, PPP exchange rates minimise misleading interna-
tional comparisons that can arise with the use of market 
exchange rates. Insurance coverage for NYS is shown in 
the online supplementary appendix. Costs included in 
this study are for procedures alone and do not include 
postoperative care, such as rehabilitation, medical 
follow-up or reinterventions.
Outcomes
The primary endpoint was total mortality. The secondary 
endpoint was repeat revascularisation. Hospitalisation 
dates were used to derive the survival time from proce-
dure to the various endpoints. Postoperative outcomes 
were considered at 30 days and 1 year. As date of death 
was not available in the NYS dataset, approximate survival 
times were calculated using death flags. The methodology 
and validation of this process is detailed in the online 
supplementary appendix.
statistical analysis
Continuous variables are expressed as mean (±SD) and 
compared using the Student’s t-test. Categorical variables 
were compared using the χ2 statistic. Kaplan-Meier curves 
and the log-rank test were used to assess survival. Logistic 
regressions were applied to estimate the different short-
term endpoints, that is, within 30 days and 1 year. Cox 
proportional hazard models were used to assess the long-
term relative risk in comparisons of the various endpoints 
in England and NYS. Proportionality hypotheses were 
verified by visual examination of log (survival) graphs to 
ensure parallel curves and by plotting Schoenfeld resid-
uals. Statistical analyses were undertaken using Stata V.14 




The study population included patients undergoing 
(n=1 42 969) or PCI (n=4 31 416) over a period of 4.67 
years in 154 centres in England and 86 in NYS. Baseline 
characteristics are shown in table 1. Among country 
differences, there was a greater proportion of women 
in NYS (P<0.001) and reported individual comorbid-
ities, as well as the Charlson score, were consistently 
higher in NYS for all procedures (all P<0.001).
Postoperative outcomes
Figure 1 shows Kaplan-Meier survival curves and table 2 
shows cumulative incidence rates over the follow-up 
period. After CABG, total mortality was lower in England 
at both 30 days (by 0.72%) and 1 year (by 3.68%) (both 
P<0.001). Likewise, after PCI, total mortality was lower 
in England at both 30 days (by 0.35%) and 1 year (by 
3.55%) (both P<0.001). In multivariable logistic regres-
sion analyses, there were no group differences in total 
mortality at 30 days after either CABG (England: HR 
1.02, 95% CI 0.94 to 1.10) or PCI (HR 1.04, 95% CI 0.99 
to 1.09). At 1 year, adjusted total mortality was lower in 
England after both CABG (HR 0.74, 95% CI 0.71 to 
0.78) and PCI (HR 0.66, 95% CI 0.65 to 0.68).
Repeat revascularisation
The combined endpoint of total mortality or repeat 
revascularisations at 30 days after CABG was 0.84% 
lower in England (P<0.001), but this was not signifi-
cant after adjustment (HR 1.01, 95% CI 0.94 to 1.09). 
At 1 year, the combined endpoint was 4.91% lower in 
England (P<0.001) and this remained significant after 
adjustment (HR 0.76 (95% CI 0.72 to 0.79). After PCI, 
this combined endpoint was 2.58% lower in England 
at 30 days (by 2.58%, P<0.001), even after adjustment 
(HR 0.64, 95% CI 0.62 to 0.66). Similarly, the combined 
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Table 1 Baseline characteristics
CABG PCI
England NYS England NYS
N 93 473 49 496 286 076 145 340
Gender (man) 79.3 72.1 73.5 68.3
Age (years) 67.6±10.1 67.2±11.0 64.8±12.1 65.1±12.2
Charlson score (median (IQR)) 4 (9) 8 (13) 3 (5) 5 (10)
Hypertension (%) 64.2 58.4 47.7 66.9
Diabetes mellitus (%) 24.3 32.9 18.6 33.9
Renal impairment (%) 2.8 13.9 2.2 11.2
Myocardial infarction (%) 10.7 27.4 44.4 40.1
Heart failure (%) 10.0 27.7 7.8 15.4
Stroke (%) 4.0 11.9 1.3 6.7
Concomitant AVR/MVR (%) 17.4 18.6 –
All comparisons between England and NYS for procedures and diagnoses were statistically significant (all P<0.001).
AVR, aortic valve replacement; CABG, coronary artery bypass grafting; MVR, mitral valve replacement; NYS, New York State; PCI, 
percutaneous coronary intervention.
Figure 1 Clinical outcomes after cardiac procedures. 
Kaplan-Meier survival curves are shown for the various 
endpoints. HR and 95% CI are derived from univariable 
Cox proportional hazards models. CABG, coronary artery 
bypass grafting; EN, England; NYS, New York State; PCI, 
percutaneous  coronary intervention.
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endpoint was also lower in England at 1 year (by 4.63%, 
P<0.001) even after adjustment (HR 0.68, 95% CI 0.68 
to 0.71).
long-term outcomes
As shown in figure 1, survival curves for total mortality 
after CABG diverged up to year 1 and converged there-
after. Over the whole follow-up period, there were no 
differences in adjusted total mortality (England: HR 
1.00, 95% CI 0.96 to 1.05) (table 3). In contrast, survival 
curves after PCI diverged from the outset. Over the 
whole follow-up period, adjusted total mortality was lower 
in England (England: HR 0.87, 95% CI 0.85 to 0.89) 
(table 3). Total mortality or repeat revascularisation was 
similar after CABG (England: HR 1.00, 95% CI 0.96 to 
1.04) and lower in England after PCI (HR 0.85, 95% CI 
0.4 to 0.87).
Costs
As shown in table 4, costs of CABG and PCI were higher 
in NYS. After adjustment for CCR and PPPs, costs in NYS 
amounted to uplifts of 3.8-fold for CABG and 3.6-fold for 
PCI.
dIsCussIOn
In this study of real-world clinical practice, we found 
no differences in 30-day total mortality after CABG or 
PCI in England and NYS, after adjustment for age and 
comorbidities. At 1 year, adjusted total mortality was 
lower in England for both CABG and PCI. Long-term 
adjusted total mortality was similar after CABG, but lower 
in England after PCI. Costs of both CABG and PCI were 
approximately fourfold higher in NYS.
Outcomes
Postoperative outcomes are usually reported in terms of 
crude 30-day mortality. Whether or not this is an appro-
priate measure of the outcome of surgery is debatable, 
but this measure is nevertheless used worldwide. We 
found no difference in 30-day total mortality between 
England and NYS for either CABG or PCI, after adjust-
ment for age, sex or comorbidities. Arguably, the effects 
of an operation extends well beyond 30 days, perhaps 
after 1 year. In this respect, we found that adjusted total 
mortality at 1 year after CABG and PCI were lower in 
England. In the long term, adjusted total mortality was 
similar for CABG, but lower in England for PCI.
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England NYS Difference (%) P value England NYS Difference (%) P value
Total mortality
≤30 day 2.31 3.03 0.72 <0.001 2.36 2.71 0.35 <0.001
≤1 year 5.35 9.03 3.68 5.16 8.71 3.55
≤2 years 7.43 10.69 3.26 7.55 11.04 3.49
≤3 years 9.63 12.32 2.69 9.80 13.62 3.82
≤4.67 years 13.93 15.44 1.51 13.76 18.33 4.57
Total mortality/repeat revascularisations
≤30 day 2.41 3.25 0.84 <0.001 4.03 6.61 2.58 <0.001
≤1 year 6.60 11.51 4.91 15.69 20.32 4.63
≤2 years 9.42 14.41 4.99 20.36 25.18 4.82
≤3 years 12.21 16.66 4.45 24.07 28.86 4.79
≤4.67 years 17.18 19.87 2.69 29.89 33.16 3.27
Cumulative outcome rates (%) were calculated from survival table. P values refer to log-rank tests.
CABG, coronary artery bypass grafting; NYS, New York State; PCI, percutaneous coronary intervention.
Table 3 Multivariable analyses
CABG PCI
OR*/HR† 95% CI P value OR*HR† 95% CI P value
Total mortality
  ≤30 days 1.02 0.94 to 1.10 0.63 1.04 0.99 to 1.09 0.09
  ≤1 year 0.74 0.71 to 0.78 <0.001 0.66 0.65 to 0.68 <0.001
  Overall 1.00 0.96 to 1.05 0.84 0.87 0.85 to 0.89 <0.001
Total mortality/repeat revascularisations
  ≤30 days 1.01 0.94 to 1.09 0.78 0.64 0.62 to 0.66 <0.001
  ≤1 year 0.76 0.72 to 0.79 <0.001 0.70 0.68 to 0.71 <0.001
  Overall 1.00 0.96 to 1.04 0.98 0.85 0.84 to 0.87 <0.001
*OR for England from multivariable logistic regression, adjusting age, sex and comorbidities for 30-day mortality/composite outcome and 
1-year mortality/composite outcome.
†HR from multivariable Cox regression, adjusting age, sex and comorbidities for total mortality/composite outcome.
CABG, coronary artery bypass grafting; NYS, New York State; PCI, percutaneous coronary intervention.
Unfortunately, administrative databases lack granu-
larity and further statistical analysis of our data is unlikely 
to shed light on the factors that contribute to observed 
differences in crude outcomes. It might be considered, 
however, that the observed differences are clinically 
acceptable, particularly in view that we are dealing with 
different healthcare systems in different countries. It is 
also possible that patients with greater comorbidity are 
being treated in NYS. On the other hand, that comorbid-
ities tend to be under-reported in England.9 This could 
explain differences in outcomes.
In keeping with other studies,10–12 we have observed 
a higher uptake of repeat coronary revascularisation 
procedures in NYS after both CABG and PCI. We did not 
assess symptom status in these populations and we cannot 
discount the possibility that higher revascularisation rates 
in the USA are associated with a better quality of life.
Costs
Costs of cardiac revascularisation in NYS described 
herein are consistent with other reports.13 An uninsured 
patient in the USA is likely to pay $70 000–$200 000 for 
a CABG, depending on the hospital and postoperative 
course. We found that costs in NYS were approximately 
fourfold higher than in England. This may be due to 
several factors. First, the USA pays more simply because 
it is wealthier. In this respect, the USA spends more per 
capita (as a percentage of growth domestic product) than 
other industrialised nation (17.1% vs 7%–11%). In 2006, 
healthcare costs per capita, adjusted for cost of living, 
were $6714 in the USA and $2880 in other industrialised 
nations. The cost for the public sector in the USA and 
England amounted to $3074 vs $2027 per person (Organ-
isation for Economic Co-operation and Development 
(OECD) median), respectively, after adjusting for cost 
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Table 4 Costs
CABG PCI
England NYS England NYS
Gross (£/$) 8884 109 904 3883 45 035
After correction for 
CCR* ($)
  – 49 005   – 20 120
 After correction for 
PPP† 
Net costs (£) 8884 33 726 3883 13 819
Net costs ($) 12 763 49 005 5607 20 120
Median costs are presented.
*The average Medicare hospital-specific CCRs were 0.45 for years 
2009, 2010 and 2011; 0.44 for 2012 and 0.43 for 2013.
†PPPs between the UK and the USA were 0.656 pounds to one 
unit dollar in 2009, 0.691 in 2010, 0.7 in 2011, 0.659 in 2012 and 
0.699 in 2013.
CABG, coronary artery bypass grafting; CCR, cost-to-charge 
ratios; NYS, New York State; PCI, percutaneous coronary 
intervention; PPPs, purchasing power parities.
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of living. Out-of-pocket expenses were also higher in the 
USA (OECD median of $857 vs $483 in 2006). Second, 
healthcare in NYS may simply be more expensive, that is, 
it pays a higher price for the same goods and services. 
In this regard, pharmaceutical spending per capita in 
the USA, adjusted for cost of living, was $1843 in 2006, 
compared with a OECD median of $1433.14 15 Higher 
charges in the USA are also accrued by diagnostics, such 
as magnetic resonance and CT scans14 and pharmaceuti-
cals. As this is an observational study, we cannot assume 
that changes in costs would necessarily translate to 
changes in clinical outcomes.
An important question is whether our findings are 
generalisable to other US states. In the analytic sample for 
NYS, 51.4% of patients were covered by either Medicare 
(46%) or Medicaid (5.4%), which compares to a total of 
63.6% coverage across the USA in 2013,16 when 30/52 
states in the USA had similar Medicare and Medicaid 
coverage to NYS (total between 30% and 40% in 2013).17
limitations
Our study has several limitations, most of which are related 
to its observational and retrospective design. First, patients 
in NYS consistently had more reported comorbidities. 
Under-reporting is recognised in England.9 Clearly, this 
could influence both short-term and long-term outcomes. 
To minimise this effect, we selected our study time from 
2009, when coding systems in England improved after 
greater usage of the Payment by Results tariff system. Second, 
we used a proxy death date for NYS data. Nevertheless, we 
have applied the same algorithm to data from England 
and obtained similar results. Third, disease severity, which 
could also affect outcomes, was not assessed, as is the norm 
in administrative datasets. Fourth, we have not explored 
other aspects of healthcare that might influence outcomes, 
including medication, differences in operator experience, 
variations in care pathways and organisational issues.18 Fifth, 
we do not have data on the aetiology of coronary disorders, 
all of which are likely to influence outcomes. Sixth, there will 
be systematic differences in coding between the two coun-
tries, and for this reason, we did not use statistical methods 
to try to match patients. Some demographic features such 
as age and sex can be compared (and indeed were very 
similar between countries), but differences observed in 
other factors, such as Charlson score, are likely to relate 
in part to differences in the accuracy with which these 
features are recorded in the different healthcare systems. 
Seventh, our findings from NYS may not be generalisable 
to the entire US healthcare system, in which the Veterans 
Association and Kaiser group may have varying coverage. 
Eighth, we have not quantified the details of treatment that 
may also have impact on outcomes, including the type of 
coronary artery graft (internal mammary or vein), type of 
stent (metal or drug eluting of first or second generation), 
type and duration of dual antiplatelet regimen, differences 
in door-to-balloon or ischaemia times and other differences 
in the management of patients with ST-elevation myocar-
dial infarction  (STEMI). Last, we have no data on socioec-
onomic status and this too is likely to influence outcomes.
COnClusIOns
This is the largest comparison of long-term clinical 
outcomes and costs after CABG and PCI in England and 
USA to date. We have found that total mortality was similar 
at 30 days and lower in England at 1 year. Costs were approx-
imately fourfold higher in NYS.
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